Previous 10 | Next 10 |
Neurocrine Biosciences, Inc. (NBIX) Q2 2019 Earnings Conference Call July 29, 2019, 16:30 ET Company Participants Kevin Gorman - CEO & Director Jane Sorensen - Head, IR Matthew Abernethy - CFO Eiry Roberts - Chief Medical Officer Kyle Gano - Chief Business Development &am...
Gainers: TREX +9.2% . RNG +9.0% . NOV +8.0% . NBIX +7.8% . MEDP +7.5% . More news on: Trex Company, Inc., RingCentral, Inc., National Oilwell Varco, Inc., Stocks on the move, Read more ...
Neurocrine Biosciences (NASDAQ: NBIX ): Q2 GAAP EPS of $0.54 beats by $0.32 . More news on: Neurocrine Biosciences, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
SAN DIEGO , July 29, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended June 30, 2019 and provided an update on the launch of INGREZZA ® (valbenazine) and its clinical development programs. ...
Introduction On Monday, Intec Pharma ( NTEC ) announced their phase 3 trial assessing their proprietary Accordion Pill-Carbidopa/Levodopa for Parkinson's disease did not prove superior to immediate-release Carbidopa/Levodopa (Sinemet). We are disappointed that the ACCORDANCE stud...
The FDA accepts for review Neurocrine Biosciences' (NASDAQ: NBIX ) marketing application seeking approval to use opicapone, a once-daily, oral catechol-O-methyltransferase (COMT) inhibitor, for the adjunctive treatment (to levodopa/carbidopa) of Parkinson's disease patients experiencing OF...
SAN DIEGO , July 10, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for opicapone, a novel, once-daily, oral, selective catechol-O-methyltransferase (COMT) i...
SAN DIEGO , July 8, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report second quarter financial results after the Nasdaq market closes on Monday, July 29, 2019 . Neurocrine will then host a conference call and webcast to discuss its ...
Quick Take BridgeBio ( BBIO ) has filed to raise gross proceeds of up to $225 million from a U.S. IPO, according to an S-1/A registration statement . The group is developing therapeutics for Mendelian diseases, or diseases arising from defects in a single gene as well as cancers with clea...
Array BioPharma is up 56% after agreeing to a sale to Pfizer for more than $10B. UniQuire, meanwhile, is higher by 8.35% after a weekend report that it's exploring a sale. More news on: BioMarin Pharmaceutical Inc., bluebird bio, Inc., Sage Therapeutics, Inc., H...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
A look at the top 10 most actives in the United States Redhill Biopharma Ltd. (RDHL) rose 41.5% to $0.5434 on volume of 82,457,301 shares FSD Pharma Inc. (HUGE) rose 9.8% to $0.1109 on volume of 60,485,300 shares NVIDIA Corporation (NVDA) rose 2.3% to $119.75 on volume of 54,756,180 shares ...
Neurocrine Biosciences Reports Second Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Second Quarter Net Product Sales of $580 Million Representing 32% Year-Over-Year Growth INGREZZA ...
Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing PR Newswire SAN DIEGO , July 18, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX...